Table 2. Studies assessing the role of... | American Society of Hematology

Table 2.

Studies assessing the role of KIR-ligand mismatch in cord blood transplantation

Reference	Willemze 2009²⁸	Brunstein 2009⁹⁴		Tanaka 2013⁹²	Garfall 2013⁹¹	Rocha 2016⁹³	Sekine 2016⁹⁷
No. of patients	218	155	102	357 AML)	80	199	204
Conditioning (%)	MA (83)	MA (100)	RIC (100)	MA (62)	MA (27)	MA (100)	MA (72)
ATG/ALG (%)	82	40	28	0	100	70	100
Single-CBT (%)	100	61	100	100	0	0	—
KIR-ligand mismatched (GvH direction) (%)	32	26	32	81	44	43	HLA C1/x patients who receive CB unit with HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 vs all other
aGVHD (2-4)	NS	NS	Higher in KIR-ligand mismatch	NS	NS	NS	NS
Risk			79% vs 57%
95% CI			59%-99% vs 44%-70%
P			.01
TRM	NS	NS	Higher in KIR-ligand mismatch	NS	—	NS	NS
Risk			27% vs 12% at 2 years
95% CI			12%-42% vs 5%-19%
P			.03
Relapse	Lower in KIR-ligand mismatch	NS	NS	NS	NS	NS	Lower in HLA-C1/x recipients who received an HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 CB unit
Risk	RR, 0.53						HR, 0.04
95% CI	0.28-0.99						1.57-31.47
P	.05						.002
OS	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	NS	NS	NS	Higher in HLA-C1/x recipients who received an HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 CB unit
Risk	RR, 2		32% vs 52% at 3 years				HR, 3.46
95% CI	1.24-3.22		15%-59% vs 47%-67%				1.46-8.20
P	.004		.03				.005

Reference	Willemze 2009²⁸	Brunstein 2009⁹⁴		Tanaka 2013⁹²	Garfall 2013⁹¹	Rocha 2016⁹³	Sekine 2016⁹⁷
No. of patients	218	155	102	357 AML)	80	199	204
Conditioning (%)	MA (83)	MA (100)	RIC (100)	MA (62)	MA (27)	MA (100)	MA (72)
ATG/ALG (%)	82	40	28	0	100	70	100
Single-CBT (%)	100	61	100	100	0	0	—
KIR-ligand mismatched (GvH direction) (%)	32	26	32	81	44	43	HLA C1/x patients who receive CB unit with HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 vs all other
aGVHD (2-4)	NS	NS	Higher in KIR-ligand mismatch	NS	NS	NS	NS
Risk			79% vs 57%
95% CI			59%-99% vs 44%-70%
P			.01
TRM	NS	NS	Higher in KIR-ligand mismatch	NS	—	NS	NS
Risk			27% vs 12% at 2 years
95% CI			12%-42% vs 5%-19%
P			.03
Relapse	Lower in KIR-ligand mismatch	NS	NS	NS	NS	NS	Lower in HLA-C1/x recipients who received an HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 CB unit
Risk	RR, 0.53						HR, 0.04
95% CI	0.28-0.99						1.57-31.47
P	.05						.002
OS	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	NS	NS	NS	Higher in HLA-C1/x recipients who received an HLA-C1-KIR2DL2, KIR2DL3, or KIR2DS2 CB unit
Risk	RR, 2		32% vs 52% at 3 years				HR, 3.46
95% CI	1.24-3.22		15%-59% vs 47%-67%				1.46-8.20
P	.004		.03				.005

ALG, anti-lymphocyte globulin; CB, cord blood; MA, myeloablative; RIC, reduced-intensity conditioning; TRM, treatment-related mortality.